Peter Mac, NICTA team up for cancer software project
21 December, 2005 by Graeme O'NeillAustralia's largest cancer research agency, Melbourne's Peter MacCallum Cancer Centre, is linking up with the National Information and Communications Technology Agency (NICTA) to develop adaptive software to sift huge datasets from microarray chips for patterns of gene activity distinctive to different cancers.
Not a gene out of place
05 December, 2005 by Graeme O'NeillGraeme O'Neill reports back from the recent CSIRO Horizons in Livestock Science conference at the Gold Coast, which addressed the progress, challenges and problems associated with redesigning livestock.
Start-up Haplomics to muscle in on gene-testing market
01 December, 2005 by Graeme O'NeillMelbourne gene-testing company Genetic Technologies (ASX:GTG), currently engaged in a protracted court case with giant US rival Applera over licensing and royalties for GTG's controversial non-coding DNA patents, has a potential rival in its own backyard.
The primordial structure of proteins
01 December, 2005 by Graeme O'NeillIs the tendency to misfold and form aggregates of fibrils and gels the true nature of proteins? Graeme O'Neill reports.
Benitec tells AGM of better times ahead
30 November, 2005 by Helen Schuller"Seeing you all here means the company has survived," the chairman of RNAi specialist Benitec (ASX:BLT) Ray Whitten, told shareholders at today's AGM in Sydney.
Farmacule grows proteins in tobacco
22 November, 2005 by Graeme O'NeillBrisbane agbiotech Farmacule BioIndustries has taken a step towards the era of molecular 'pharming' by producing vitronectin, a high-value human protein used in medical research, in genetically modified tobacco plants.
The great divide: therapeutic cloning
22 November, 2005 by Ruth BeranShould Australia lift its ban on therapeutic cloning? Few topics in Australian science have generated such strong opinions. Ruth Beran reports.
Australian biotech hears the tiger's roar
21 November, 2005 by David BinningDavid Binning finds a wealth of opportunities for Australian integration with other Asian biotech industries.
Good press drove October biotech enthusiasm: Intersuisse
18 November, 2005 by Helen SchullerBiotech shares bucked the trend during the month of October - the Intersuisse biotechnology index gained 6.6 per cent in contrast to the All Ordinaries and the Nasdaq Biotech Index, which fell by 3.9 per cent and 3.8 per cent respectively.
UQ team helps tap into the alcoholic brain
10 November, 2005 by Graeme O'NeillResearchers at the University of Queensland have discovered fundamental differences in patterns of gene expression in alcoholic versus normal brains.
Probiomics nets govt grant
10 November, 2005 by Helen SchullerProbiomics (ASX:PCC), formerly VRI BioMedical, has received an AusIndustry Commercial Ready grant for the next stage of its molecular discovery program.
Dr Findlay's DNA casebook provides a Ripper yarn
09 November, 2005 by Graeme O'NeillCould an Australian gene-test company's uniquely sensitive new DNA fingerprinting technique finally finger history's most notorious serial murderer, London's Jack the Ripper?
CSIRO, Benitec strengthen RNAi patent positions
24 October, 2005 by Graeme O'NeillThe legal mists are lifting from Black Mountain in Canberra, and Mountain View in California, clarifying the ownership of key patents on RNA interference (RNAi) gene silencing technology.
Researchers address the meaning of the genomic revolution
12 October, 2005 by Graeme O'NeillGenetics genomics have disturbed science's dreams of explaining human nature and individuality as merely a function of the activity of genes, modulated by environmental factors, according to University of Queensland Federation Fellow Professor Paul Griffiths.
ChemGenex pinpoints inflammation gene
10 October, 2005 by Graeme O'NeillDiabetes- and oncology-gene hunter ChemGenex Pharmaceuticals (ASX:CXS) now has solid evidence that a particular variant of the SEPS-1 gene, already identified as a trigger for Type 2 diabetes, is a strong risk factor for a broad range of chronic inflammatory disorders.
